Dr. Davidson-Moncada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1230 York Ave
# 39
New York, NY 10065Phone+1 212-327-7858Fax+1 212-327-7319
Education & Training
- Royal Free Hospital and University College London Medical SchoolClass of 2002
Clinical Trials
- MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer Start of enrollment: 2018 Jun 04
Publications & Presentations
PubMed
- 2 citationsMyeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia.Ibrahim Aldoss, Parastou Tizro, Davsheen Bedi, James K Mangan, Mary C Clark
Haematologica. 2023-12-01 - 4 citationsEfficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia.Sonali P Barwe, Anne Kisielewski, Ezio Bonvini, John Muth, Jan Davidson-Moncada
Journal of Clinical Medicine. 2022-02-28 - 192 citationsFlotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt
Blood. 2021-02-11
Abstracts/Posters
- A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART¬ Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid LeukemiaJan K Davidson-Moncada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart¬ Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associat...Jan K Davidson-Moncada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Effect of Ara-C on T-Cell Function and Flotetuzumab Activity in Pediatric Acute Myeloid LeukemiaJan K Davidson-Moncada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
- Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers SymposiumJanuary 21st, 2023
- Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed/Refractory AML at American Society of Hematology (ASH) 64th Annual MeetingDecember 11th, 2022
- Phase 2 Findings Demonstrate Wugen’s Investigative Allogeneic ActivityJune 15th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: